What is SBFM's earnings growth forecast for 2026-2026?
(NASDAQ: SBFM) Sunshine Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Sunshine Biopharma's earnings in 2026 is -$6,039,450.
In 2026, SBFM is forecast to generate -$1,633,939 in earnings, with the lowest earnings forecast at -$1,569,863 and the highest earnings forecast at -$1,681,996.
What is SBFM's revenue growth forecast for 2026-2026?
(NASDAQ: SBFM) Sunshine Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Sunshine Biopharma's revenue in 2026 is $35,493,315.
In 2026, SBFM is forecast to generate $25,530,294 in revenue, with the lowest revenue forecast at $24,529,106 and the highest revenue forecast at $26,281,185.
What is SBFM's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: SBFM) forecast ROA is -5.85%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 10.96%.
What is SBFM's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: SBFM) Sunshine Biopharma's current Earnings Per Share (EPS) is -$12.90. In 2026, SBFM's EPS is forecast to hit -$3.26 (min: -$3.14, max: -$3.36).
What is SBFM's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: SBFM) forecast ROE is -7.59%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.